Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141.
Robert L. Ferris(University of Pittsburgh), Maura L. Gillison(The University of Texas MD Anderson Cancer Center), Makoto Tahara(National Cancer Center Hospital East), Francis P. Worden(Georgetown University), Mark Lynch(Fluidigm (United States)), Jérôme Fayette(Université Claude Bernard Lyon 1), Naomi Kiyota(Kobe University Hospital), Justin Kopit(Gdańsk Medical University), Lisa Licitra(University of Milan), James W. Shaw(University of Illinois Chicago), Everett E. Vokes(University of Chicago), A. Dimitrios Colevas(Cancer Institute (WIA)), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Manish Monga(Institut Gustave Roussy), George R. Blumenschein(The University of Texas MD Anderson Cancer Center), Robert I. Haddad(Georgetown University), William J. Geese(Institut Gustave Roussy), Stefan Kasper(Essen University Hospital), Caroline Even(Institut Gustave Roussy), J. Guigay(Centre Antoine Lacassagne)
Cited by 53
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Human Papillomavirus and Rising Oropharyngeal Cancer Incidence in the United States
|Journal of Clinical Oncology|2011|3.6k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k